Loading...
Market
Will Revuforj receive EMA approval by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from the European Medicines Agency
Story
FDA Approves Syndax's Revuforj for Acute Leukemia, Shares Rise 4%
Nov 15, 2024, 10:53 PM
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), developed by Syndax Pharmaceuticals, for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation. This approval, announced on Friday, is significant as Revuforj is the first and only menin inhibitor to treat this specific type of leukemia. The drug is approved for both adult and pediatric patients one year and older. Following the announcement, Syndax Pharmaceuticals' shares rose by 4% in after-hours trading.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
